Completed
PHASE3
INTERVENTIONAL
NCT05586971
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Interventions
Name:
Tigulixostat
Type:
DRUG
Description:
Xanthine Oxidase Inhibitor
Name:
Allopurinol
Type:
DRUG
Description:
Xanthine Oxidase Inhibitor
Name:
Placebo
Type:
DRUG
Description:
Matching placebo
Primary Outcomes
Measure:
The proportion of subjects with sUA levels <6.0 mg/dL sustained at months 4, 5, and 6
TimeFrame:
Up to Month 6
Description:
Serum uric acid (sUA) level will be measured at Month 4,5, and 6
Trial Information
NCT ID
NCT05586971
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
LG Chem
Last Updated
December 15, 2025